SENSEX NIFTY
Jan 03, 2013, 01.26 PM IST | Source: Moneycontrol.com

Dr Reddys Labs gains 2% on Finasteride launch in US

Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.

Healthcare firm Dr Reddy's Laboratories was the top gainer on the Sensex, rising more than 2 percent on Thursday after the company launched Finasteride tablets (1 mg), a bioequivalent generic version of Propecia in the US market.

The company's ANDA for Finasteride tablets has been awarded a 180-day period of marketing exclusivity in the US on January 2.

"The Propecia tablets has US sales of approximately USD 136 million MAT for the most recent 12 months ending October 2012, according to IMS Health," the company said in a release.

At 10:36 hours IST, the stock gained 2.13 percent to Rs 1,877 on the Bombay Stock Exchange.

Also Read
Geometric surges on acquisition of 3Cap Technologies
Jet Air rises 6% on impending stake sale deal with Etihad

Dr Reddys Labs stock price

On October 23, 2014, Dr Reddys Laboratories closed at Rs 3054.35, up Rs 16.30, or 0.54 percent. The 52-week high of the share was Rs 3353.85 and the 52-week low was Rs 2250.00.


The company's trailing 12-month (TTM) EPS was at Rs 145.02 per share as per the quarter ended June 2014. The stock's price-to-earnings (P/E) ratio was 21.06. The latest book value of the company is Rs 547.59 per share. At current value, the price-to-book value of the company is 5.58.

READ MORE ON  Dr Reddy's Laboratories
Set email alert for

ADS BY GOOGLE

video of the day

All portents good; optimistic for next few Diwali's: Damani

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.